脂蛋白(a)与高分辨率MRI评估的颅内斑块易损性及长期卒中复发相关
回顾性纳入210例症状性颅内动脉粥样硬化性狭窄患者,分析脂蛋白(a)水平与HRMRI斑块易损特征及卒中复发的关系。高脂蛋白(a)组斑块内出血、表面不规则和正性重构比例更高,中位随访32.5个月高脂蛋白(a)与卒中复发风险相关(HR=2.65,95%CI 1.28-5.47,p=0.009)。
要点
- 高脂蛋白(a)组斑块内出血比例52.50% vs 低组30.59%(p=0.01)。
- 高脂蛋白(a)组表面不规则47.50% vs 低组26.47%(p=0.02)。
- 高脂蛋白(a)且≥2个易损斑块特征者卒中复发风险最高(45.5%,p=0.004)。
核心结论
- 高脂蛋白(a)水平与症状性颅内动脉粥样硬化性狭窄患者卒中复发风险增加相关,部分效应由易损斑块特征介导。
研究设计与样本
- 回顾性收集210例连续的症状性颅内动脉粥样硬化性狭窄患者,均行脂蛋白(a)测量和高分辨率磁共振成像,采用Cox比例风险模型分析。
关键影像表现/征象
- 易损斑块特征定义为斑块内出血、正性重构、斑块表面不规则和2级斑块强化;高脂蛋白(a)组斑块内出血、表面不规则和正性重构出现率均高于低脂蛋白(a)组。
诊断标准与关键数值
- 脂蛋白(a)采用二分类分组;4组分类按脂蛋白(a)水平和易损斑块特征数目划分;高脂蛋白(a)与卒中复发风险HR=2.65(95%CI 1.28-5.47,p=0.009);高脂蛋白(a)且≥2个易损斑块特征者卒中复发率45.5%(p=0.004);中介分析显示约27.0%的预后效应通过易损斑块特征介导。
临床应用与阅片要点
- 对症状性颅内动脉粥样硬化性狭窄患者,可结合脂蛋白(a)水平与HRMRI易损斑块特征(斑块内出血、表面不规则、正性重构)评估卒中复发风险。
局限性
- 原文为回顾性收集。
- 原文结论指出部分效应由易损斑块特征介导,但未报告未介导部分的机制。
- 原文未报告样本量估算或置信区间宽度的局限说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Lipoprotein(a) [Lp(a)] was related to increased risk of major adverse cardiovascular events. We aimed to explore the association between Lp(a) levels and intracranial plaque vulnerable features identified through high-resolution magnetic resonance imaging (HRMRI), along with their prognostic significance.
MATERIALS AND METHODS: A total of 210 consecutive patients with symptomatic intracranial atherosclerosis stenosis (sICAS) who underwent Lp(a) measurement and HRMRI were retrospectively collected. Plaque vulnerable features were defined as intraplaque hemorrhage (IPH), positive remodeling, plaque surface irregularity, and grade 2 plaque enhancement. Binary classification of Lp(a) levels was applied to assess its relationships with plaque features and long-term stroke recurrence using Cox proportional hazard models.
RESULTS: Patients with a high Lp(a) level had a higher presence of IPH (30.59% versus 52.50%, p = 0.01), surface irregularity (26.47% versus 47.50%, p = 0.02), and positive remodeling (40.00% versus 62.50%, p = 0.02). Over a median follow-up period of 32.5 months (Q1-Q3: 14.0-56.3 months), higher Lp(a) levels were linked to stroke recurrence risk (HR = 2.65; 95% CI: 1.28-5.47; p = 0.009). In a 4-group classification according to Lp(a) and plaque vulnerable features, patients with high Lp(a) and ≥ 2 vulnerable plaque features had the highest risk of stroke recurrence (45.5%; p = 0.004). Causal mediation analysis indicated that approximately 27.0% of the prognostic impact of Lp(a) was mediated through vulnerable plaque features.
CONCLUSION: Elevated Lp(a) levels are linked to an increased stroke recurrence risk in sICAS patients, with part of this effect mediated by vulnerable plaque characteristics.
KEY POINTS: Question Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease and plaque vulnerability, but the simultaneous evaluation of Lp(a) and vulnerable plaque features remains unknown. Findings Elevated Lp(a) levels are independently associated with vulnerable plaque features, all of which are linked to clinical outcomes. Clinical relevance This might offer novel targets to mitigate the atherogenic impact of Lp(a) and provide a clinically available, noninvasive tool for monitoring the clinical benefits of Lp(a)-lowering therapies in the future.
引用
- Huang Q, Liu L, Liu W, et al. Lipoprotein(a) associates with high-resolution MRI-assessed intracranial plaque vulnerability and long-term stroke recurrence. Eur Radiol. 2025. PMID: 40522405. doi:10.1007/s00330-025-11748-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。